Pipamperone is a typical antipsychotic of the butyrophenone family and is used to treat schizophrenia and as a sleep aid for depression.
Effect
Pharmacodynamics
Pipamperone binds primarily to 5-HT2A receptors, with nearly equal affinity to D4 receptors and moderate affinity to 5-HT2C, D2-3, and alpha-adrenoceptors. Pipamperone has a 15-fold higher affinity for D4 than for D2 receptors. Binding to the above receptors results in the antipsychotic and antidepressant effects.
Pharmacokinetics
Pipamperone is taken orally and metabolized in the liver. Excretion is mainly by the kidneys. The half-life is about 16-27 hours.
Aktories, Förstermann, Hofmann, Starke: Allgemeine und spezielle Pharmakologie und Toxikologie, Elsvier, 2017
Editorial principles
All information used for the content comes from verified sources (recognised institutions, experts, studies by renowned universities). We attach great importance to the qualification of the authors and the scientific background of the information. Thus, we ensure that our research is based on scientific findings.
Markus Falkenstätter, BSc Author
Markus Falkenstätter is a writer on pharmaceutical topics in Medikamio's medical editorial team. He is in the last semester of his pharmacy studies at the University of Vienna and loves scientific work in the field of natural sciences.
Mag. pharm. Stefanie Lehenauer Lector
Stefanie Lehenauer has been a freelance writer for Medikamio since 2020 and studied pharmacy at the University of Vienna. She works as a pharmacist in Vienna and her passion is herbal medicines and their effects.
The content of this page is an automated and high-quality translation from DeepL. You can find the original content in German here.